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ABSTRACT
Oxazole-containing macrocycles represent a prom-
ising class of anticancer agents that target
G-quadruplex DNA. We report the results of
spectroscopic studies aimed at defining the
mode, energetics and specificity with which a
hexaoxazole-containing macrocycle (HXDV) binds
to the intramolecular quadruplex formed by the
human telomeric DNA model oligonucleotide
d(T2AG3)4 in the presence of potassium ions. HXDV
binds solely to the quadruplex nucleic acid form, but
not to the duplex or triplex form. HXDV binds
d(T2AG3)4 with a stoichiometry of two drug mole-
cules per quadruplex, with these binding reactions
being coupled to the destacking of adenine resi-
dues from the terminal G-tetrads. HXDV binding to
d(T2AG3)4 does not alter the length of the quad-
ruplex. These collective observations are indicative
of a nonintercalative ‘terminal capping’ mode of
interaction in which one HXDV molecule binds to
each end of the quadruplex. The binding of HXDV to
d(T2AG3)4 is entropy driven, with this entropic
driving force reflecting contributions from favorable
drug-induced alterations in the configurational
entropy of the host quadruplex as well as in net
hydration. The ‘terminal capping’ mode of binding
revealed by our studies may prove to be a general
feature of the interactions between oxazole-con-
taining macrocyclic ligands (including telomestatin)
and intramolecular DNA quadruplexes.
INTRODUCTION
Telomeres are nucleoprotein structures located at the
ends of eukaryotic chromosomes. Maintenance of these
structures is essential for the prevention of chromo-
some degradation and illegitimate recombination (1).
Telomerase, a ribonucleoprotein complex with reverse
transcriptase activity, is responsible for the maintenance
of telomeres (2,3). Inhibition of telomerase activity is
associated with telomere shortening and subsequent
activation of DNA damage responses that include cell
cycle arrest, senescence and apoptosis (4–10). These eﬀects
have rendered telomerase an appealing target for antic-
ancer therapeutics (11–15). The appeal of telomerase
as an anticancer drug target is bolstered by the fact that
its activity is found in 85–90% of all human tumors, but
not in normal cells (6,7,10,16). As an example, telomerase-
targeted therapy has been suggested for the treatment
of malignant gliomas, since they are telomerase-positive,
while normal brain tissue has no telomerase activity (17).
Like telomerase inhibition, deprotection of telomeric
DNA can also cause the activation of DNA damage
responses (8,18–22). In some human tumor cells, telomere
deprotection induced by over-expression of a dominant-
negative form of the telomeric DNA-binding protein
TRF2 results in ATM-dependent apoptosis or senescence
(8,9). Furthermore, inactivation of the telomeric DNA-
binding protein Cdc13p in yeast results in RAD9-
dependent G2 arrest and MEC1-dependent apoptosis
(18,19). Since MEC1 is the functional yeast homolog
of ATM, the latter result suggests that deprotection of
telomeres activates a common ATM signaling pathway
in both yeast and humans.
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single-stranded overhangs (G-tails) with 16–35 tandem
repeats of the 50-T2AG3-30 hexameric sequence (23,24).
These G-tails can readily adopt thermodynamically stable
G-quadruplex structures both in vitro (25–32) and in vivo
(33,34). Compounds that stabilize G-quadruplex DNA
have the potential for inhibiting the activities of both
telomerase and telomeric DNA-binding proteins by deny-
ing them access to the telomere (11–15,35). To date, a
diverse array of G-quadruplex-stabilizing compounds has
been identiﬁed, including macrocyclic oxazoles (20,36–43),
anthraquinones (44,45), acridines (46–50), cationic por-
phyrins (51–60), bistriazoles (61), perylenes (62–64),
ethidium derivatives (65,66), ﬂuorenones (67), pentacyclic
acridinium salts (68–70) and ﬂuoroquinophenoxazines
(71,72). Among these compounds, the macrocyclic oxa-
zoles and the bistriazoles exhibit a particularly high degree
of selectivity for G-quadruplex relative to duplex DNA
(37,43,61).
Telomestatin (a natural product isolated from
Streptomyces anulatus) has proven to be one of the more
potent and selective inhibitors of telomerase (36,37). This
compound is a macrocyclic torand consisting of seven
oxazole rings and one thiazoline ring. It exhibits
cytotoxicity (IC50) versus neuroblastoma cell lines ranging
from 0.8 to 4.0mM (73). In this connection, oxazole-
containing macrocycles represent a promising new class of
G-quadruplex-targeting anticancer agents. We have pre-
viously shown that a macrocyclic hexaoxazole (HXDV,
see structure in Figure 1) inhibits the growth of human
lymphoblastoma RPMI 8402 cells with an IC50 of 0.4mM
(43). Our studies also revealed that HXDV binds and
thermally stabilizes the structure formed in the presence of
potassium ions by an oligomer [d(T2AG3)4] that contains
four repeats of the multiply repeated sequence in the
G-tails of human telomeric DNA (Figure 1) (43). Recent
studies indicate that the potassium-stabilized structure
adopted by d(T2AG3)4 in solution is an intramolecular
(3þ1) G-quadruplex in which three strands are oriented
in one direction and the fourth strand is oriented in the
opposite direction (29–32). While binding and stabilizing
the d(T2AG3)4 quadruplex, HXDV did not interact with
duplex DNA derived from salmon testes (ST DNA) (43).
Although oxazole-containing macrocycles like telomes-
tatin and HXDV have been shown to bind and stabilize
G-quadruplex DNA, the mode and energetics associated
with the G-quadruplex binding of such compounds
remains to be delineated. In the current study, we deﬁne
the mode, energetics and speciﬁcity with which HXDV
binds human telomeric quadruplex DNA, which we model
with the d(T2AG3)4 sequence. Our results indicate that
HXDV binds solely to the quadruplex and not to the
duplex or triplex form of nucleic acids. In addition, our
studies also reveal that HXDV binds to d(T2AG3)4 via
an entropically driven ‘terminal capping’ mode of inter-
action. To the best of our knowledge, these results provide
the ﬁrst experimental demonstration for this mode of
interaction by an oxazole-containing macrocycle, which
hitherto has been only theorized based on computational
simulations (37,43).
MATERIALS AND METHODS
Ligandand nucleicacid molecules
HXDV was synthesized as described previously (43).
Stock solutions of this compound were prepared in
dimethyl sulfoxide (DMSO) and stored at  208C. All
DNA oligomers were obtained in their HPLC-puriﬁed
forms from Integrated DNA Technologies (Coralville, IA,
USA). The concentrations of all unlabeled and 2-amino-
purine (AP)-labeled DNA solutions were determined
spectrophotometrically using the following extinction
coeﬃcients at 260nm and 908C( e260–908C) [in units of
(molstrand/l)
 1 cm
 1]: 231100 2300 for d(T2AG3)4;
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d(T2AG3)4: 5′-TTAGGGTTAGGGTTAGGGTTAGGG-3′
9AP: 5′-TTAGGGTTAPGGGTTAGGGTTAGGG-3′
15AP: 5′-TTAGGGTTAGGGTTAPGGGTTAGGG-3′
21AP: 5′-TTAGGGTTAGGGTTAGGGTTAPGGG-3′
15,21AP: 5′-TTAGGGTTAGGGTTAPGGGTTAPGGG-3′
AF: 5′-AF-TAGGGTTAGGGTTAGGGTTAGGGAT-3′
AF-Dab: 5′-AF-TAGGGTTAGGGTTAGGGTTAGGGAT-Dab-3′ 
Figure 1. (A) The chemical structure of HXDV. (B) Base sequences of the seven DNA oligomers used in this study. In these sequences, AP denotes
the ﬂuorescent base 2-aminopurine, AF denotes the ﬂuorescent dye Alexa Fluor 546 and Dab denotes the quencher dabcyl.
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223100 4200 for 21AP and 208300 5100 for
15,21AP. These extinction coeﬃcients were determined
by enzymatic digestion and subsequent colorimetric
phosphate assay using previously established protocols
(74). The concentrations of all Alexa Fluor 546-labeled
DNA solutions were also determined spectrophotometri-
cally. However, these determinations were based on the
extinction coeﬃcient for the Alexa Fluor dye at 554nm
and 258C( e554–258C¼112000M
 1 cm
 1) reported in the
2005 Molecular Probes Handbook. The r(UG4U) oligo-
mer was obtained in its PAGE-puriﬁed form from
Dharmacon Research Inc. (Lafayette, CO, USA). The
concentrations of r(UG4U) solutions were determined
using an e260–908C of 70000 7500 (molstrand/l)
 1 cm
 1,
with this e260–908C value being derived as described above
for the unlabeled and AP-labeled DNA oligomers.
Salmon testes DNA, as well as all DNA and RNA
polynucleotides, were obtained from Sigma (St. Louis,
MO, USA), and used without further puriﬁcation.
Polynucleotide solution concentrations were determined
using the following extinction coeﬃcients in units of
(molnucleotide/l)
 1 cm
 1: e260–258C¼6000 for p(dA) 
p(dT); e265–258C¼8700 for p(dT); e258–258C¼9800 for
p(rA) and e260–258C¼9350 for p(rU).
Temperature-dependent spectrophotometry
Temperature-dependent absorption experiments were
conducted on an AVIV Model 14DS Spectrophotometer
(Aviv Biomedical, Lakewood, NJ, USA) equipped with
a thermoelectrically controlled cell holder. Quartz cells
with a pathlength of 1.0cm were used for all the
absorbance studies. Temperature-dependent absorption
proﬁles were acquired at either 260 (for duplex and
triplex) or 295 (for quadruplex) nm with a 5s averaging
time. The temperature was raised in 0.58C increments, and
the samples were allowed to equilibrate for 1.5min at each
temperature setting. In the quadruplex melting studies,
the concentrations of d(T2AG3)4, 9AP, 15AP, 21AP and
15,21AP were 5mM in strand (120mM in nucleotide),
while the concentration of r(UG4U) was 20mM in strand
(120mM in nucleotide). When present in these quadruplex
studies, the HXDV concentration was 20mM. In the
duplex and triplex melting studies, the nucleic acid
concentration was 15mM in base pair (30mM in nucleo-
tide) or 15mM in base triple (45mM in nucleotide) and the
HXDV concentration, when present, was 15mM. The
buﬀer for all the UV melting experiments contained
10mM EPPS (pH 7.5). In addition, suﬃcient KCl was
added to each solution to bring the total K
þ concentration
to either 150mM for d(T2AG3)4 and p(rA) p(dT), 2mM
for r(UG4U), 50mM for ST DNA, 250mM for
p(dA) 2p(dT) or 20mM for p(rA) 2p(rU). Prior to
their use in UV melting experiments, all nucleic acid
solutions were preheated at 908C for 5min and slowly
cooled to room temperature over a period of 4h.
Circulardichroism (CD) spectroscopy
Circular dichroism experiments were conducted at 358C
on an AVIV Model 202 spectropolarimeter equipped with
a thermoelectrically controlled cell holder. A quartz cell
with a 1cm pathlength was used for all the CD studies.
CD spectra were recorded from 340 to 240nm in 1nm
increments with an averaging time of 2s. The buﬀer
conditions were 10mM EPPS (pH 7.5) and suﬃcient
KCl to bring the total K
þ concentration to 150mM. The
concentration of d(T2AG3)4 was 8mM in strand (192mM
in nucleotide), and, when present, the osmolalities of
glycerol and ethylene glycol were 2.0.
Steady-state fluorescence spectroscopy
All steady-state ﬂuorescence experiments were conducted
on an AVIV model ATF105 spectroﬂuorometer equipped
with a thermoelectrically controlled cell holder. The solu-
tion conditions for the steady-state ﬂuorescence experi-
ments were identical to those described above for the
CD experiments.
Fluorescence quantum yield values ( ) for 9AP, 15AP,
21AP and their HXDV complexes were determined
relative to quinine sulfate in 1N H2SO4, which was
assigned a value of 0.546at 258C (75). In these measure-
ments, the excitation wavelength was set at 310nm, with
the excitation and emission bandwidths being set 5nm.
The pathlengths of the quartz cell used in these measure-
ments were 0.2cm in the excitation direction and 1cm
in the emission direction. The 9AP, 15AP and 21AP
concentrations were 18mM in strand (432mM in nucleo-
tide), while the concentration of quinine sulfate was
20mM. When present, the HXDV concentration (90mM)
was chosen so as to ensure that essentially all the
DNA was ligand-bound under the solution conditions
employed. Fluorescence emission spectra were acquired
at 258C from 605 to 320nm in 1nm increments with a
1s averaging time. All ﬂuorescence emission spectra were
corrected by subtraction of the corresponding spectra of
buﬀer alone or buﬀer plus HXDV.
The characterizations of AF and AF-Dab were
conducted with the excitation wavelength set at 540nm
and the excitation and emission bandwidths set at 5nm.
The pathlength of the quartz cell used in these measure-
ments was 1cm in both the excitation and emission
directions. Fluorescence emission spectra were acquired at
either 25 or 908C from 720 to 545nm in 1nm increments
with a 1s averaging time. These emission spectra were
corrected by subtraction of the corresponding spectra of
buﬀer alone. Temperature-dependent characterizations
of AF-Dab were conducted with the emission wavelength
set at 579nm and the averaging time set at 10s. The
temperature was raised in 18C increments, and the samples
were allowed to equilibrate for 1min at each temperature
setting. The concentrations of AF and AF-Dab were
always 1mM in strand (25mM in nucleotide), while the
concentration of HXDV, when present, was 50mM.
For the HXDV titration experiments, which were
conducted at temperatures ranging from 15 to 458C,
1–10ml aliquots of ligand (at concentrations ranging from
500mM to 2mM in DMSO) were sequentially added to
solutions of 15,21AP that were 10mM in strand (240mM
in nucleotide). After each addition, the sample was left
to equilibrate for 3min, whereupon the emission spectrum
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were corrected by subtraction of the corresponding spectra
of buﬀer alone or buﬀer plus the appropriate amount of
HXDV. In these measurements, the excitation wavelength
was set at 310nm, with the excitation and emission band-
widths being set 5nm. The pathlengths of the quartz cell
used in these measurements were 1cm in the excitation
direction and 0.2cm in the emission direction.
Concentrations of free and bound HXDV ([HXDV]free
and [HXDV]bound) were derived from the HXDV-induced
changes in 15,21AP ﬂuorescence in the following manner.
Fluorescence intensities at inﬁnite HXDV concentration
(I1) were determined by ﬁtting semilogarithmic plots
of ﬂuorescence intensity (I) versus total HXDV concen-
tration ([HXDV]total) with the following sigmoidal
relationship:
I ¼ I1 þ
I0   I1
1 þ
½HXDV total
½HXDV 1=2
   p : 1
In this relationship, I0 is the ﬂuorescence intensity in the
absence of HXDV, p the Hill slope and [HXDV]½ is the
HXDV concentration at which half of the AP-labeled
DNA sites are bound. The I1 values obtained from ﬁts
with Equation (1) were used to determine values of
[HXDV]bound by proportionality. Values of [HXDV]free
were then determined by subtraction of [HXDV]bound
from [HXDV]total.
Time-resolved fluorescence anisotropy
Time-resolved ﬂuorescence anisotropy measurements were
conducted at 258C on a PTI EasyLife LS ﬂuorescence
lifetime system ﬁtted with a 310nm LED light source, ﬁlm
polarizers in both the excitation and emission directions,
and a 350nm long pass ﬁlter (Chroma Technology Corp.,
Rockingham, VT, USA) in the emission direction. The slit
width in the excitation direction was set at 6mm. The
ﬂuorescence decay curves were acquired logarithmically
in 400 channels with a 0.5s integration time. The start and
end delays of the acquisitions were 70 and 115ns, respec-
tively. The instrument response function was detected
using light scattered by a dilute suspension of nondairy
creamer, with the emission polarizer oriented parallel to
the excitation polarization and no cut-on ﬁlter in place.
The DNA concentration was 10mM in strand (240mMi n
nucleotide), and, when present, DNA-saturating concen-
trations of HXDV (90mM) were employed. Each ﬁnal
decay proﬁle reﬂected an average of six independent scans
and was deconvolved in the Felix32 program (PTI Inc.,
London, Ontario, CANADA). The solution conditions for
these time-resolved ﬂuorescence experiments were identical
to those described above for the CD experiments.
Fluorescence intensity decays measured with the emis-
sion polarizer oriented either parallel {IVV(t)} or perpen-
dicular {IVH(t)} to the excitation polarization were best ﬁt
by the following sum of three exponentials:
IðtÞ¼
X 3
i¼1
 ie t= i 2
In this relationship, the values of  i are the amplitudes
of each component and the values of  i are the corres-
ponding ﬂuorescence lifetimes. IVV(t) and IVH(t) were then
deconvolved simultaneously with a magic angle decay
{D(t)} using the following relationships:
IVVðtÞ¼
DðtÞ 1 þ 2rðtÞ ½ 
3
, 3a
IVHðtÞ¼
DðtÞ 1   rðtÞ ½ 
3G
: 3b
In these relationships, G is the instrumental correction
factor and r(t) is the anisotropy decay, which was best ﬁt
by the following sum of two exponentials:
rðtÞ¼ 1e t= 1 þ  2e t= 2 4
The limiting anisotropy at time zero {r(0)} was derived
from the sum of  1 and  2. Values of G ranged from 0.99
to 1.03, and were determined using the following
relationship:
G ¼
Ð
IHVðtÞdðtÞ Ð
IHHðtÞdðtÞ
: 5
RESULTS AND DISCUSSION
HXDVbindingisspecificforquadruplexrelativetoduplexor
triplex nucleic acidforms
We sought to evaluate the ability of HXDV to bind and
thermally stabilize the duplex, triplex and quadruplex
forms of nucleic acids. Toward this end, we monitored the
UV absorbances of the nucleic acids as a function of
temperature in the absence and presence of HXDV. The
melting of duplex and triplex nucleic acids is generally
associated with a hyperchromic shift at 260nm (76,77),
while the melting of quadruplex nucleic acids is associated
with a hypochromic shift at 295nm (26,78). Thus, the
temperature-dependent absorbances of duplexes and
triplexes were monitored at 260nm, with corresponding
quadruplex absorbances being monitored at 295nm. ST
DNA, p(rA) p(rU), p(rA) p(dT), p(dA) 2p(dT),
p(rA) 2p(rU), d(T2AG3)4 and r(UG4U) were used as
representative models of a DNA duplex, an RNA duplex,
a hybrid DNA RNA duplex, a DNA triplex, an RNA
triplex, a DNA quadruplex and an RNA quadruplex,
respectively. All the UV melting studies were conducted at
pH 7.5 in the presence of potassium ions.
Figure 2 shows the UV melting proﬁles (depicted in
their ﬁrst-derivative forms) of d(T2AG3)4, ST DNA,
p(dA) 2p(dT), r(UG4U), p(rA) p(dT) and p(rA) 
2p(rU) in the absence (ﬁlled circles) and presence (open
circles) of HXDV. Note that the presence of HXDV does
not impact the thermal transitions of the ST DNA (B) and
p(rA) p(dT) (E) duplexes. Furthermore, it does not alter
the Watson–Crick (WC) thermal transitions [which reﬂect
the conversion of duplex and single strand to all single
strand (77)] of the p(dA) 2p(dT) (C) and p(rA) 2p(rU)
(F) triplexes. These results suggest that neither ST DNA,
p(rA) p(dT), p(dA) p(dT), nor p(rA) p(rU) interacts
Nucleic Acids Research, 2007, Vol. 35,No. 10 3275with HXDV. In other words, HXDV does not appear to
interact with DNA DNA, RNA RNA or RNA DNA
hybrid duplexes. Not only does the presence of HXDV fail
to alter the WC thermal transitions of the p(dA) 2p(dT)
and p(rA) 2p(rU) triplexes, it also fails to impact the
corresponding Hoogsteen (HG) thermal transitions [which
reﬂect the conversion of the triplex to duplex and single
strand (77)] of these two triplexes. Thus, neither the DNA
nor the RNA triplex form appears to be capable of serving
as a binding substrate for HXDV.
Although the presence of HXDV does not alter the
thermal stabilities of the duplex and triplex nucleic acids
noted above, it increases the thermal stabilities of the
d(T2AG3)4 and r(UG4U) quadruplexes (Figure 2A and D,
respectively). These HXDV-induced thermal enhance-
ments are indicative of ligand binding to the host
quadruplexes. The transition temperature (Ttran) corre-
sponding to the minimum of the d(T2AG3)4 melting
proﬁle increases from 63.08C in the absence of HXDV to
80.58C in the presence of the ligand (Figure 2A). HXDV
increases the thermal stability of r(UG4U) to a lesser
extent than d(T2AG3)4, with the Ttran of r(UG4U)
increasing from 103.0 to 104.08C (Figure 2D). It is
tempting to suggest that the reduced extent of thermal
enhancement aﬀorded the tetramolecular quadruplex
formed by r(UG4U) (79,80) relative to the monomolecular
quadruplex formed by d(T2AG3)4 (27,32) may reﬂect a
comparatively reduced aﬃnity of HXDV for the RNA
quadruplex versus the DNA quadruplex. However, it is
also possible that the diﬀerential impact of HXDV
binding on the thermal stabilities of r(UG4U) and
d(T2AG3)4 reﬂects the markedly diﬀering Ttran-values of
the two quadruplexes.
In the aggregate, our UV melting results are consistent
with HXDV binding solely to quadruplex and not to
duplex and triplex nucleic acid forms. With the exception
of telomestatin, few other compounds approach this
degree of quadruplex-binding speciﬁcity (38,39,61,81).
Steady-statefluorescence studies of d(T2AG3)4site-
specifically substituted with2-aminopurine are consistent
withHXDV-induced destacking of theadenines at positions
15and 21, butnot theadenine at position 9
While the UV melting studies described in the preceding
section are indicative of an interaction between HXDV
and d(T2AG3)4, they provide little information regarding
the molecular nature of the ligand–quadruplex complex.
Toward this goal, we substituted the adenine residue
at either position 9, 15 or 21 of d(T2AG3)4 with AP
(see Figure 1B). Control UV melting studies of the result-
ing AP-substituted oligomers (9AP, 15AP and 21AP)
reveal that the AP substitutions induce little or no
alteration in the thermal stability of d(T2AG3)4, nor do
they alter the interaction of d(T2AG3)4 with HXDV (see
Figure S1 of the Supplementary Data).
We monitored the impact of HXDV binding on the
ﬂuorescence of 9AP, 15AP and 21AP, with the resulting
emission spectra being shown in Figure 3A–C, respectively.
HXDV binding induces a substantive increase in the
ﬂuorescence of 15AP and 21AP, while minimally aﬀecting
the ﬂuorescence of 9AP. We quantiﬁed these ﬂuorescence
changes by analyzing the ﬂuorescence intensities of 9AP,
15AP and 21AP and their HXDV complexes to derive
the quantum yield ( ) values listed in Table 1. HXDV
binding increases the   values of 15AP and 21AP by 0.013
and 0.007, respectively. In contrast, the   value of 9AP
is essentially unchanged by HXDV. These ﬂuorescence
results are consistent with HXDV binding being coupled
to the destacking of the AP bases at positions 15 and 21,
but not the base at position 9.
HXDV binds d(T2AG3)4viaa‘terminal capping’rather
thanan intercalative mode of interaction
Previously reported NMR and computational studies
(29–32) of d(T2AG3)4 and related oligomers in the
presence of potassium ions indicate that the adenine
residues in the edgewise loops (A15 and A21) are stacked
on opposing terminal G-tetrads (schematically depicted
in Figure 4). Unlike these two adenine residues, the
adenine residue in the double-chain reversal loop (A9)
adopts an unstacked conformation. Our ﬂuorescence
studies described above suggest that HXDV binding to
d(T2AG3)4 induces the destacking of A15 and A21, but
not A9. A potential mode of interaction that would be
consistent with these results is one in which two HXDV
molecules bind to the quadruplex, one at each end of
the structure (schematically depicted in Figure 4). This
‘terminal capping’ model for the HXDV–d(T2AG3)4
interaction excludes the involvement of an intercalative
binding mode. To test this hypothesis, we used a ﬂuore-
scence resonance energy transfer (FRET) approach to
monitor the impact of HXDV binding on the length of the
d(T2AG3)4 quadruplex. Intercalation is typically asso-
ciated with an increase in the length of the host nucleic
acid structure. In contrast, a ‘capping’ type of interaction
should not alter the length of the nucleic acid.
We designed the AF-Dab and AF variants of
d(T2AG3)4 shown in Figure 1B. AF-Dab has an Alexa
Fluor 546 molecule conjugated to its 50-end and a dabcyl
molecule conjugated to its 30-end. AF has only the 50-
conjugated Alexa Fluor 546 molecule. Through a FRET-
mediated process, dabcyl (the acceptor) quenches the
ﬂuorescence of Alexa Fluor 546 (the donor) with an
associated Fo ¨ rster distance (R0)o f2 9A ˚ (as reported in the
2005 Molecular Probes Handbook). Given this R0 value,
the increase in quadruplex length of  3.5A ˚ that might be
induced by the intercalation of a single ligand molecule
would yield a detectable decrease in the extent of dabcyl-
induced quenching of Alexa Fluor 546 ﬂuorescence.
Figure 5 shows the ﬂuorescence emission spectra at 258C
of the quadruplex forms of AF (A) and AF-Dab (B) in
the absence and presence of HXDV. In addition, the
corresponding emission spectrum of the single-stranded
form of AF-Dab is also presented (Figure 5B). Note the
enhanced ﬂuorescence intensity of the single-stranded
relative to the quadruplex form of AF-Dab, an obser-
vation reﬂecting the increased distance between the
Alexa Fluor 546 and dabcyl functionalities in the single-
stranded versus the quadruplex form. The presence of
HXDV induces a small decrease in the ﬂuorescence
3276 Nucleic Acids Research, 2007, Vol. 35, No. 10−0.002
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transition of the remaining duplex into single strands.intensity of quadruplex AF-Dab. This result argues
against an intercalative mode of binding, since such a
mode of interaction should induce an opposite eﬀect
(i.e. increase the ﬂuorescence intensity of quadruplex
AF-Dab). The HXDV-induced decrease in quadruplex
AF-Dab ﬂuorescence does not appear to reﬂect a decrease
in the distance between the Alexa Fluor 546 and dabcyl
moieties, as a similar decrease in the ﬂuorescence of AF
is also induced by the presence of HXDV (Figure 5A).
Control ﬂuorescence melting studies conﬁrm the bind-
ing of HXDV to the AF-Dab and AF quadruplexes
used in our FRET experiments (see Figure S2 of the
Supplementary Data).
The nonintercalative mode of HXDV-quadruplex bind-
ing suggested by the FRET results is not surprising if
one considers the structural propensities of HXDV itself.
We constructed and reﬁned a structural model for HXDV
using the Sybyl software suite (Tripos Inc., St. Louis, MO,
USA). This model is depicted in Figure 6. Signiﬁcantly,
HXDV adopts a concave rather than a planar structure,
with the plane formed by three of its oxazole moieties
being angled  1508 relative to the plane formed by its
other three oxazole moieties (see side view of Figure 6).
It is likely that such a nonplanar ligand molecule would
have diﬃculty stably intercalating between neighboring
G-tetrads. Taken together, the computational, FRET and
AP ﬂuorescence results described above, are fully con-
sistent with a nonintercalative ‘terminal capping’ mode
of interaction between HXDV and d(T2AG3)4.
HXDV binds d(T2AG3)4withastoichiometry oftwo
ligand molecules perquadruplex
The ‘terminal capping’ model for the HXDV–d(T2AG3)4
interaction invokes the binding of one ligand molecule to
each end of the quadruplex. We sought to determine
experimentally the stoichiometry with which HXDV binds
d(T2AG3)4. To this end, we designed the 15,21AP variant
of d(T2AG3)4 shown in Figure 1B, in which the adenine
residues at both positions 15 and 21 are substituted with
AP residues. As was the case with a single AP substitution
at position 9, 15 or 21, the double AP substitution at
positions 15 and 21 induces little or no alteration in the
thermal stability of d(T2AG3)4, nor does it alter the
interaction of d(T2AG3)4 with HXDV (see Figure S1 of
the Supplementary Data). We monitored the ﬂuorescence
of 15,21AP as a function of added HXDV. Figure 7A
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Figure 3. Steady-state ﬂuorescence emission spectra at 258C of 9AP (A),
15AP (B) and 21AP (C) in the absence (solid lines) and presence
(dashed lines) of saturating concentrations of HXDV. The solution
conditions were 10mM EPPS (pH 7.5) and suﬃcient KCl to bring the
total K
þ concentration to 150mM.
Table 1. Fluorescence quantum yields ( ) of 9AP, 15AP, 21AP and
their HXDV complexes at 258C
a
Sample   ( 0.001)
9AP 0.034
9AP-HXDV 0.035
15AP 0.004
15AP-HXDV 0.017
21AP 0.014
21AP-HXDV 0.021
aSolution conditions were 10mM EPPS (pH 7.5) and suﬃcient KCl to
bring the total K
þ concentration to 150mM.
3278 Nucleic Acids Research, 2007, Vol. 35, No. 10shows a representative ﬂuorescence titration proﬁle
(depicted semilogarithmically) acquired at 258C. This
ﬂuorescence titration proﬁle was analyzed as described
in the Materials and Methods to yield concentrations of
free and bound HXDV ([HXDV]free and [HXDV]bound,
respectively). These concentrations enabled us to con-
struct the binding curves shown in Figure 7B and C, in
which [HXDV]bound/[15,21AP]total (where [15,21AP]total
denotes the total concentration of 15,21AP quadruplex)
is plotted as a function of [HXDV]free. We ﬁt the resulting
binding curves with the following formalisms for one or
two binding sites (83):
One Site :
½HXDV bound
½15,21AP total
¼
K1½HXDV free
1 þ K1½HXDV free
6
Two Sites :
½HXDV bound
½15,21AP total
¼
K1½HXDV free þ 2K1K2½HXDV 
2
free
1 þ K1½HXDV free þ K1K2½HXDV 
2
free
7
In these formalisms, Ki denotes the association constant
for the binding of HXDV to a given site on 15,21AP.
A comparison of Figure 7B and C reveals that the forma-
lism for two binding sites aﬀords a substantively better ﬁt
( 
2¼0.004) of the binding curve than the corresponding
formalism for one binding site ( 
2¼0.011). Note that
applying a formalism for three binding sites (not shown)
did not signiﬁcantly improve the ﬁt aﬀorded by the two-
site formalism (i.e. no further reduction in  
2 was
observed). Collectively, these results indicate that HXDV
binds to d(T2AG3)4 with a stoichiometry of two ligand
molecules per quadruplex, a binding stoichiometry con-
sistent with our proposed ‘terminal capping’ mode of
interaction.
The bindingof HXDV tod(T2AG3)4is entropydriven
In addition to conducting ﬂuorescence titration experi-
ments at 258C, we also conducted similar experiments
at 15, 35 and 458C. The binding curves ([HXDV]bound/
[15,21AP]total versus [HXDV]free) resulting from these
temperature-dependent studies are shown in Figure 8A.
Fitting these binding curves with the formalism for two
binding sites [Equation (7)] enabled us to derive values
of K1 and K2 at each temperature, with these values
being listed in Table 2. At all the temperatures examined,
K1 (which ranges from 9.2 10
4 to 1.9 10
5M
 1)i s
greater than K2 (which ranges from 3.0 to 5.9 10
4M
 1).
Thus, one HXDV molecule binds the host quadruplex
with a greater aﬃnity than the other.
We analyzed the temperature dependence of K1 and K2
using the following van’t Hoﬀ relationship:
lnðKÞ¼  
 H
R
  
1
T
þ
 S
R
8
where  H and  S are the respective enthalpy and entropy
changes for the binding of HXDV to the quadruplex.
Equation (8) postulates that van’t Hoﬀ plots of
ln(K) versus 1/T will be linear, with the slopes and
y-intercepts of these plots yielding estimates for  H and
 S, respectively.
A15
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“Terminal Capping” Mode of Interaction
d(T2AG3)4 d(T2AG3)4–2HXDV
10
Figure 4. Schematic representation of the ‘terminal capping’ model for the interaction between HXDV and d(T2AG3)4. In the absence of HXDV, the
adenine residues at positions 15 and 21 (A15 and A21) are stacked on the terminal G-tetrads, while the adenine residue at position 9 (A9) does not
engage in such stacking interactions. Upon the binding of an HXDV molecule to each end of the quadruplex (i.e. ‘terminal capping’ of the
quadruplex), A15 and A21 become destacked, while A9 remains essentially unaﬀected. Adenine bases are depicted in red, guanine bases are depicted
in green and thymine bases are depicted in orange. HXDV molecules are depicted in yellow.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3279Figure 8B shows the van’t Hoﬀ plots constructed using
the temperature-dependent K data listed in Table 2. The
values of  H and  S derived from linear regression
analyses of these plots and subsequent application of
Equation (8) are listed in Table 3. In addition, Table 3 also
lists the free energy changes that accompany the binding
reactions at 358C(  G35). These  G35 values were derived
using the corresponding values of K and the standard
relationship
 G ¼  RTlnðKÞ: 9
Inspection of the thermodynamic data in Table 3
reveals positive  H and  S values for the binding of
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Figure 5. (A) Fluorescence emission spectra at 258C of the quadruplex
form of AF in the absence (solid line) and presence (dashed line) of
saturating concentrations of HXDV. (B) Fluorescence emission spectra
at 258C of the quadruplex form of AF-Dab in the absence (solid line)
and presence (dashed line) of saturating concentrations of HXDV.
This panel also shows the corresponding emission spectrum of the
single-stranded form of AF-Dab in the absence of HXDV (dashed-
dotted line). The 258C spectrum of single-stranded AF-Dab reﬂects
the spectrum of AF-Dab acquired at 908C (a temperature at which
AF-Dab is fully denatured) after correction for the temperature
dependence of AF ﬂuorescence. This correction was achieved by
multiplying the 908C spectrum of AF-Dab by the ratio of the 258CA F
spectrum relative to the 908C AF spectrum. The solution conditions
were as described in the legend to Figure 3.
Top view
Side view
~150 º
Figure 6. Top and side views of a structural model for HXDV, in
which carbon atoms are depicted in gray, oxygen atoms are depicted
in red, nitrogen atoms are depicted in blue and hydrogen atoms are
depicted in white. Note the nonplanar nature of the hexaoxazole
torand, as highlighted by the side view. The SYBYL 7.2 software suite
(Tripos Inc.) was used to build a starting 3D structure of the ligand
molecule. This structure was subsequently energy minimized using the
Tripos force ﬁeld with 1000 iterations of the conjugate gradient
method. A nonbonded cutoﬀ of 8A ˚ was used in these calculations,
and atomic charges were assigned based on the Gasteiger–Hu ¨ ckel
method (82).
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Figure 7. (A) Semilogarithmic depiction of the ﬂuorescence proﬁle for
the titration of 15,21AP with HXDV at 258C. I370 denotes the buﬀer-
corrected ﬂuorescence emission intensity at 370nm. The solid line
reﬂects the ﬁt of the experimental data points with Equation (1).
(B, C) Binding curves of HXDV to 15,21AP derived from the ﬂuore-
scence titration proﬁle shown in panel A. The solid line in panel B
reﬂects the ﬁt of the experimental data using the formalism for one
binding site [Equation (6)], while the solid line in panel C reﬂects the ﬁt
of the data using the formalism for two binding sites [Equation (7)].
The solution conditions were as described in the legend to Figure 3.
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Figure 8. (A) Binding curves of HXDV to 15,21AP derived from
ﬂuorescence titration proﬁles acquired at 15, 25, 35 and 458C. The solid
lines reﬂect ﬁts of the experimental data points with Equation (7).
(B) van’t Hoﬀ plots {ln(K) versus 1/T} depicting the temperature
dependence of the association constants for the binding of HXDV to its
two target sites on 15,21AP. The solid lines reﬂect linear ﬁts of the
experimental data points with Equation (8).
Table 2. Temperature dependence of the association constants (K) for
the binding of HXDV to its two target sites on 15,21AP
a
Temperature (8C) K1
b (M
 1) K2
b (M
 1)
15 (1.1 0.1) 10
5 (3.0 0.2) 10
4
25 (9.2 0.3) 10
4 (3.4 0.1) 10
4
35 (1.9 0.1) 10
5 (4.3 0.1) 10
4
45 (1.7 0.1) 10
5 (5.9 0.3) 10
4
aSolution conditions were as described in the footnote to Table 1.
bValues of K were derived from ﬁts of the binding curves shown in
Figure 8A using Equation (7). The indicated uncertainties reﬂect the
standard deviations of the experimental data from the ﬁtted curves.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3281HXDV to both quadruplex sites. Thus, the binding of
HXDV to both sites is enthalpically unfavorable, while
being entropically favorable. Viewed as a whole, these
results demonstrate that HXDV binding to the host
d(T2AG3)4 quadruplex is entropically driven.
Definingthemolecularoriginsoftheentropicdrivingforcefor
theHXDV–d(T2AG3)4binding reactions
One commonly invoked explanation for entropically
driven ligand-nucleic acid binding reactions is the coupled
release of counterions. However, salt-dependent binding
studies (not shown) suggest that the aﬃnity of HXDV
for d(T2AG3)4 is unaﬀected by changing ionic strength.
This result is not surprising given the noncharged nature
of HXDV. It is therefore unlikely that the entropic
driving force for the HXDV–d(T2AG3)4 binding reactions
reﬂects signiﬁcant contributions from coupled counterion
release.
A second commonly invoked explanation for entropi-
cally driven binding reactions is the coupled release of
constrained water molecules. We sought to explore this
possibility by using an osmotic stress approach to
characterize the hydration changes, if any, that accom-
pany the binding of HXDV to 15,21AP. In the osmotic
stress approach, one monitors the impact of neutral
solutes or cosolvents (osmolytes) on the ligand-DNA
association constants (K). An osmolyte-induced increase
in K reﬂects a net release of water molecules in con-
junction with binding, while an osmolyte-induced decrease
in K reﬂects a net uptake of water molecules. We
employed ethylene glycol (MW¼62.1g/mol) and glycerol
(MW¼92.1g/mol) as the osmolytes in our studies, since
their molecular weights are suﬃciently small relative
to that of HXDV so as to minimize the potential for the
introduction of volume exclusion (crowding) eﬀects.
Control CD studies reveal that the structure of
d(T2AG3)4 is unaﬀected by the presence of ethylene
glycol or glycerol at the osmolality (2.0) used in the
osmotic stress studies (see Figure S3 of the Supplementary
Data).
Table 4 lists the K values derived from ﬁts of binding
curves acquired at 358C in the absence and presence of
either ethylene glycol or glycerol. The presence of neither
osmolyte signiﬁcantly alters the value of K2, with any
observed diﬀerences in K2 being almost within the
experimental uncertainty. In contrast, the presence of
both osmolytes induces a modest increase in the value of
K1 from (1.9 0.1) to (2.8–2.9 0.2) 10
5M
 1. These
collective results suggest that HXDV binding to at least
one of the two sites on d(T2AG3)4 may be accompanied by
a net release of water molecules, a hydration change that
could contribute, at least in part, to the entropic driving
force for the binding of HXDV to d(T2AG3)4.
Another potential explanation for the entropic nature
of the driving force underlying the HXDV–d(T2AG3)4
binding reactions is a concomitant increase in the
conﬁgurational entropy of the host DNA. We explored
this possibility by using time-resolved ﬂuorescence aniso-
tropy to monitor the impact of HXDV binding on the
conformational dynamics of d(T2AG3)4. Speciﬁcally, we
evaluated how HXDV binding aﬀects the mobilities of the
AP residues in 9AP and 21AP. The low ﬂuorescence
quantum yield of unbound 15AP (see Table 1) precluded
our use of this AP-labeled quadruplex in the ﬂuorescence
anisotropy studies.
Figure 9 shows a representative set of ﬂuorescence
intensity decays for 9AP, 21AP and their HXDV
complexes with the emission polarizer oriented either
parallel (IVV) or perpendicular (IVH) to the excitation
polarization. These polarized ﬂuorescence intensity decays
were deconvolved as described in the Materials and
Methods to yield the anisotropy decay parameters listed
in Table 5. The anisotropy decays were best described by
the sum of two exponential terms [Equation (4)], with
associated r(0) values ranging from 0.308 to 0.417. The
longer of the two rotational correlation times ( 1) reﬂects
the overall tumbling of the quadruplex, while the shorter
rotational correlation time ( 2) reﬂects the internal motion
of the AP residue in the quadruplex. HXDV binding
increases the mobility of the AP residue at position 21
(  2¼ 0.33ns), while exerting essentially no impact
on the mobility of the AP residue at position 9
(  2¼ 0.03ns). This diﬀerential impact of HXDV on
the mobilities of the AP residues at positions 9 and 21
is consistent with the steady-state ﬂuorescence measure-
ments described above revealing the binding-induced
destacking of the AP residue at position 21, but not at
position 9. Recall that these steady-state ﬂuorescence
measurements also revealed the binding-induced destack-
ing of the AP residue at position 15. Thus, it is reasonable
to suggest that HXDV binding would likely increase
the mobility of this residue as well. In the aggregate, our
time-resolved ﬂuorescence anisotropy results suggest
Table 3. Thermodynamic parameters for the binding of HXDV to its
two target sites on 15,21AP at 358C
Site  G35
a (kcal/mol)  H
b (kcal/mol)  S
b (cal/mol K)
1  7.4 0.1 þ3.8 2.1 þ36.0 7.0
2  6.5 0.1 þ4.0 0.7 þ34.4 2.1
aValues of  G35 were calculated from the appropriate K-values listed
in Table 2 using Equation (9), with the indicated uncertainties reﬂecting
the maximum possible errors in K as propagated through this equation
bValues of  H and  S were determined from ﬁts of the van’t Hoﬀ
plots shown in Figure 8B using Equation (8). The indicated uncertain-
ties reﬂect the standard deviations of the experimental data from the
ﬁtted lines
Table 4. Osmolyte dependence of the association constants (K) for the
binding of HXDV to 15,21AP at 358C
a
Osmolyte Osmolality (osm) K1
b (M
 1) K2
b (M
 1)
None 0 (1.9 0.1) 10
5 (4.3 0.1) 10
4
Ethylene glycol 2.0 (2.8 0.2) 10
5 (4.8 0.3) 10
4
Glycerol 2.0 (2.9 0.2) 10
5 (3.8 0.2) 10
4
aBuﬀer conditions were as described in the footnote to Table 1.
bValues of K were derived as described in the footnote to Table 2.
3282 Nucleic Acids Research, 2007, Vol. 35, No. 10that favorable HXDV-induced alterations in the conﬁg-
urational entropies of the edgewise loops of d(T2AG3)4
contribute to the entropic driving force for the HXDV–
d(T2AG3)4 binding reactions. In addition, the ﬂuore-
scence anisotropy results also lend further support to the
‘terminal capping’ model for the mode of the HXDV–
d(T2AG3)4 interaction.
SUMMARY AND CONCLUSIONS
The studies described here demonstrate that the
macrocyclic hexaoxazole HXDV binds solely to the
G-quadruplex form of nucleic acids under physiological
conditions, with no detectable binding to duplex or triplex
forms. This behavior may prove to be a general feature
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Figure 9. Polarized ﬂuorescence decay proﬁles at 258C for 9AP (A), 21AP (C) and their complexes with HXDV (B and D, respectively). The decay
proﬁle with the emission polarizer oriented parallel to the excitation polarization (IVV) is depicted in red, while the decay proﬁle with the emission
polarizer oriented perpendicular to the excitation polarization (IVH) is depicted in blue. In each panel, the hollow circles represent the experimental
data points, while the solid lines reﬂect the nonlinear least squares ﬁts of the data with Equation (2). The inset in each panel shows the
autocorrelation functions of the weighted residuals for the ﬁts of the corresponding decay proﬁles. The solution conditions were as described in the
legend to Figure 3.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3283of macrocyclic oxazole-containing ligands, as the natural
product telomestatin (a heptaoxazole-containing macro-
cycle) appears to exhibit a similar degree of binding
speciﬁcity (38,39,61,81). The bistriazoles are the only
other class of compounds reported to date that approach
this degree of quadruplex binding speciﬁcity (61).
Signiﬁcantly, this degree of target speciﬁcity is likely to
be an important determinant of the therapeutic utility of
quadruplex-directed agents.
A broad range of spectroscopic and computational
evidence is also presented indicating that HXDV binds the
G-quadruplex formed by the human telomeric d(T2AG3)4
sequence in the presence of K
þ ions via a nonintercalative
‘terminal capping’ mode in which one ligand molecule
binds to each end of the quadruplex. Furthermore, the
binding of HXDV to d(T2AG3)4 is entropy driven, with
this thermodynamic driving force reﬂecting contributions
from favorable binding-induced alterations in the con-
ﬁgurational entropies of the edgewise loops of the host
quadruplex as well as in net hydration. Hurley and
coworkers used docking and molecular dynamics simula-
tions to propose a ‘terminal capping’ binding model for
the interaction of telomestatin with d(T2AG3)4 (37). Our
studies described here provide the ﬁrst experimental
demonstration for the G-quadruplex DNA binding of an
oxazole-containing macrocycle via a ‘terminal capping’
mode. This mode of interaction with G-quadruplex DNA
may be a common feature of the oxazole-containing
macrocyclic class of compounds.
The recently reported high-resolution structures of
G-quadruplexes adopted by human telomeric DNA
model oligonucleotides (25,27,32) form a tempting data-
base for structure-based drug design eﬀorts. However,
such eﬀorts should be undertaken with caution, since drug
binding can be coupled to conformational changes in the
host quadruplex that are diﬃcult to mimic in computa-
tional studies, particularly docking methodologies.
An intercalative mode of interaction is typically asso-
ciated with a drug-induced lengthening of the host DNA.
It is important to note that drug-induced conformational
changes in the host DNA need not be restricted to an
intercalative mode of interaction, since our studies
described here suggest that they can also occur in conjunc-
tion with a ‘terminal capping’ mode of interaction.
Yang and coworkers have proposed a model for human
telomeric DNA in which the quadruplex structure formed
by d(T2AG3)4 is multiply repeated along the length of the
30-terminal overhang region of the telomeric DNA (30).
This overhang region of human telomeric DNA consists
of   16–35 repeats of the 50-T2AG3-30 sequence (23,24).
Thus, the 30-terminal overhang region of human telomeric
DNA could potentially contain as many as eight repeats
of the quadruplex structure formed by d(T2AG3)4. Our
present results imply that oxazole-containing macrocyclic
ligands like HXDV and telomestatin could conceivably
bind to these repeating telomeric quadruplex structures
with a stoichiometry of at least one and perhaps two
ligand molecules per quadruplex structure.
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